ATRA
Atara Biotherapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$8.29-1.19%
Price as of Jul 20, 2026
ATRA financials
Atara Biotherapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M |
| Cost of revenue | $21.2M | $21.0M | $8.9M | $270.0M |
| Gross profit | $99.6M | $107.9M | -$313.0K | -$206.4M |
| Operating expenses | $63.7M | $191.4M | $275.7M | $74.1M |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M |
| EBITDA | $38.6M | -$75.7M | -$266.0M | -$222.3M |
| Basic EPS | $2.61 | $-11.41 | $-65.18 | $-55.96 |
| Diluted EPS | $2.57 | $-11.41 | $-65.18 | $-55.96 |
| Balance sheet | ||||
| Cash & equivalents | $8.5M | $25.0M | $25.8M | $92.9M |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M |
| Stockholders’ equity | -$38.5M | -$97.3M | -$99.2M | $126.6M |
| Total debt | $52.8M | $43.8M | $57.9M | $71.7M |
| Net debt | $44.3M | $18.8M | $32.0M | -$21.2M |
| Cash flow | ||||
| Operating cash flow | -$50.9M | -$68.7M | -$193.0M | -$270.4M |
| Capital expenditure | $0.00 | -$246.0K | -$1.2M | -$4.2M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |